Biotech Stocks News: What’s Going on With LIXT, PTE, QLGN and ATNM Stocks Today?


Today, many of the top trending stocks are part of two distinct categories. Big news out of the pharmaceutical sector has several microcap biotech stocks in the green. Last week, Sunshine Biopharma (NASDAQ:SBFM) saw shares skyrocket on the news of positive cancer treatment results. While the company’s growth was short lived, this week has brought more exciting news from biotech producers. According to Wall Street Reporter, “emerging technologies and healthcare research innovations are unleashing new exponential growth opportunities.”

Biochemical/biotech research scientist team working with microscope
Source: Mongkolchon Akesin /

This week brings the culmination of positive announcements from several pharmaceutical and biotech producers. The sectors struggled earlier this year as momentum caused by the Covid-19 vaccine race subsided. However, widespread momentum across both sectors has pushed many small companies into the green today. Some names have even soared above penny stock status, though it is unclear if they will stay there. Additionally, some biotech stocks are still climbing, demonstrating that type of growth that is impossible to ignore.

Let’s take a closer look at the companies reporting important advancements and what they may mean for investors.

Biotech Stocks Roundup

  • Lixte Biotechnology (NASDAQ:LIXT) has surged by an impressive 196% today. The last time the drug company made headlines it was for shares rising without a clear catalyst. Today, it has one. Lixte has reported positive data regarding LB-100, its “lead clinical cancer compound.” This news caused LIXT stock to double in premarket trading today. And it hasn’t stopped since. It is likely to pass $200 per share before prices stabilize.
  • PolarityTE (NASDAQ:PTE) is the day’s next biggest winner. It rose 40% in premarket trading and hasn’t stopped climbing since. As of this writing, it is up 107% for the day. The company, which specializes in regenerative tissue products, has received its fourth patent allowance. CEO Richard Hague claims that this type of progress will increase value for shareholders. The heavy trading volume that PTE stock has experienced today indicates that investors agree.

More Cancer Treatment Success

  • Qualigen (NADSAQ:QLGN) is also rising today after reporting progress in its cancer treatment. The clinical stage biotech producer recently presented three posters at the American Association of Cancer Research conference. In the presentation, Qualigen reported progress on its QN-302 therapeutic program. According to Chairman and CEO Michael Poirier, the company’s findings “illustrate promising in vivo anti-proliferative activity against pancreatic cancer and metastatic prostate cancer.” As of this writing, shares are up 48% for the day, making it a clear winner among biotech stocks.
  • Actinium Pharmaceuticals (NYSEMKT:ATNM) is the day’s next highest gainer. The stock has seen some volatility but is up 31% for the day at the time of writing. This morning, the target radiotherapies producer announced it had entered into a license and supply agreement with Swedish pharmaceutical producer Immedica Pharma AB. The agreement is for Antibody Radiation Conjugate Iomab-B. Today’s gains have pushed it out of the penny stock category to almost $7 per share.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Samuel O’Brient did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Samuel O’Brient has been covering financial markets and analyzing economic policy for three-plus years. His areas of expertise involve electric vehicle (EV) stocks, green energy and NFTs. O’Brient loves helping everyone understand the complexities of economics. He is ranked in the top 15% of stock pickers on TipRanks.

Article printed from InvestorPlace Media,

©2023 InvestorPlace Media, LLC